SIVs are completed for the neurodegenerative disease trial


This month GCT team has completed all scheduled Site Initiation Visits for the phase II, double-blind, placebo-controlled study in patients with mild-moderate Alzheimer’s Disease.

This USA based clinical trial aims to evaluate the safety, tolerability and preliminary efficacy of the investigational product.

GCT is responsible for the full scope of services: project management, site management, monitoring, IRB interactions and regulatory support in the U.S.

Pictured: a PET scanner
Image credit: Jens Maus, in public domain

Subscribe to our mailing list

Marketing Permissions

Please select all the ways you would like to hear from Global Clinical Trials (GCT):

You can unsubscribe at any time by clicking the link in the footer of our emails. Please see our Privacy Policy. We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.


GCT is a CRO experienced in performing clinical research in the USA, Europe, Russia and India.

We are a full-service clinical development provider, offering feasibility analysis, regulatory submission, site selection, project management, monitoring, data management, logistics, and more.

Go social with us

Follow us on social networks:

Privacy policy, Terms of service, Site map, Employees login



© 2001—2021 Global Clinical Trials, LLC

All rights reserved.